News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
The company is developing point-of-care tests for monitoring kidney function (penKid) and endothelial dysfunction in patients at risk of heart failure.
In the study, the POC assay produced a result in 15 minutes with comparable performance to a high-sensitivity laboratory assay in ruling out AMI.
The test uses the same blood draw of a routine health exam and was designed to be unaffected biotin, a vitamin supplement that may skew some lab test results.
The framework, called HEAL, could be used as an early screening test for AAA and as a personal health management tool. In addition, it may be applicable to other complex diseases.
The financing will be used to further development of a handheld device, which is being designed to be used with a high-sensitivity troponin assay.
